Pristimerin

Pristimerin has anticancer activity , treatment with Pristimerin may be a potential strategy for the suppression of hypoxia-induced metastasis through the reversal of hypoxia-induced stem cell characteristics and EMT in cancer cells. Pristimerin down-regulates the expression of pro-inflammatory mediators through blocking of NF-κB activation by inhibiting interconnected ROS/IKK/NF-κB signaling pathways, can effectively inhibit both arthritic inflammation and cartilage and bone damage in the joints.

Product Specifications

CAS Number

1258-84-0

Product Name Alternative

Pristimerin | Celastrol-methylether | UNII-28ZK7PR57S

Purity

>98% (HPLC)

Solubility

DMSO : 20 mg/mL 43.04 mM; H2O : < 0.1 mg/mL

Smiles

CC1=C (C (=O) C=C2C1=CC=C3C2 (CCC4 (C3 (CCC5 (C4CC (CC5) (C) C (=O) OC) C) C) C) C) O

Molecular Formula

C30H40O4

Molecular Weight

464.64

Storage Conditions

Storage temperature: -20°C. Stability: ≥ 2 years

Notes

For research use only.

Other Product Names

Methyl (2S,4aS,6aR,12bR,14aR,14bR) -10-hydroxy-2,4a,6a,9,12b,14a-hexamethyl-11-oxo-1,2,3,4,4a,5,6,6a,11,12b,13,14,14a,14b-tetradecahydropicene-2-carboxylate